Navigation Links
Mylan Reports a 23% Increase in Fourth Quarter 2012 Adjusted Diluted EPS to $0.65
Date:2/27/2013

PITTSBURGH, Feb. 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2012.Financial Highlights

  • Adjusted diluted EPS of $0.65 for the three months ended December 31, 2012 compared to $0.53 for the same prior year period, an increase of 23%
  • Total revenues of $1.72 billion for the three months ended December 31, 2012 compared to $1.53 billion for the same prior year period, an increase of 13%
  • On a GAAP basis, diluted EPS of $0.39 for the three months ended December 31, 2012 compared to $0.30 for the same prior year period, an increase of 30%
  • Adjusted diluted EPS of $2.59 for the year ended December 31, 2012 compared to $2.04 for the same prior year period, an increase of 27%
  • Total revenues of $6.80 billion for the year ended December 31, 2012 compared to $6.13 billion for the same prior year period, an increase of 11%
  • On a GAAP basis, diluted EPS of $1.52 for the year ended December 31, 2012 compared to $1.22 for the same prior year period, an increase of 25%
  • Adjusted operating cash flow of $1.12 billion for the year ended December 31, 2012, an increase of 27%, on a GAAP basis, cash flow from operating activities of $949 million for the year ended December 31, 2012
  • Completed the repurchase of approximately 18.0 million shares of common stock for approximately $500 million during the three months ended December 31, 2012
  • Mylan Chief Executive Officer, Heather Bresch commented: "2012 was an outstanding year for Mylan, with top-line growth of 11% and bottom line growth of 27% versus last year. With 2012 adjusted diluted earnings per share of $2.59, we delivered earnings at the high end of our updated guidance range. This record performance again is a testament to the strength and diversity of our global platfor
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

    Related medicine technology :

    1. Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
    2. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
    3. Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast
    4. Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
    5. Mylan Announces Pricing of Senior Notes
    6. Moodys and Standard & Poors Upgrade Mylan to Investment Grade Credit Ratings
    7. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
    8. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
    9. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
    10. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
    11. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
    (Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
    (Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
    Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
    ... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported ... Arena reported a lower net loss allocable to common stockholders in ... share, compared to a net loss allocable to common stockholders in ... share, and a net loss allocable to common stockholders in the ...
    ... TessArae® LLC, a global leader in resequencing microarray-based ... solutions for genetic testing of the mutations that ... TessArae,s expertise in microarray-based resequencing with novel nucleotide ... for all targeted mutations in multiple genes of ...
    Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 2Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 3Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 4Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 5Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 6Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 7Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 8Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments 9TessArae Delivers Lower Cost Option to Genetic Testing Market 2
    (Date:4/24/2014)... me out to the ballgame, doesn,t exactly conjure up ... likely culprits include French fries, soda and the occasional ... play youth baseball, eating unhealthy food during practices and ... researchers at Wake Forest Baptist Medical Center. The study, ... Obesity , found that high-calorie snacks and sugar-sweetened drinks ...
    (Date:4/24/2014)... the new Institute for Biomedical Sciences at Georgia ... federal grant to develop novel therapeutics against Respiratory ... the Eunice Kennedy Shriver National Institute Of Child ... of Health will support Plemper,s drug development goals ... one distinct alternative compound. , Infections by RSV, ...
    (Date:4/24/2014)... prescription opioid overdose deaths was outlined yesterday in the ... of agencies in the U.S. Department of Health and ... providers to expand their use of medications to treat ... number of misperceptions that have limited access to these ... can be used in combination with behavior therapies to ...
    (Date:4/24/2014)... the first in the world to discover a gene ... jaw. , Ameloblastoma is an odontogenic tumour with a ... often found in the posterior of the lower jaw. ... deficiencies in the jaws as well as loss of ... need for surgery and the recurrence of ameloblastoma, but ...
    (Date:4/24/2014)... The National Science Foundation has awarded LSU Health ... Undergraduates (REU) Site grant in the amount of ... undergraduates from diverse social and educational backgrounds, underrepresented ... area. The project will provide students with ... 2014-16. It will be led by Principal ...
    Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4
    ... a healthy diet appears to lower blood pressure in ... in women with high blood pressure, according to a ... ,The American Heart Association estimates that high ... 1 billion individuals worldwide. The most common-and deadly-result is ...
    ... here allegedly committed suicide Tuesday morning , with police attributing ... of the orthopaedics department, was found dead at around 7.00 ... south Delhi. ,Sharma, who is said to have ... around 6.00 a.m. to monitor his patients. After 20 minutes ...
    ... a super sleuth of potentially deadly prescription drug reactions. ... RADAR (Research on Adverse Drug Events and Reports) ... swoop in to investigate early signs of trouble years ... ,A new study by Bennett, the A.C. ...
    ... recently examined how researchers in Tanzania are training rats ... researchers' efforts "capitalize" on the rats' strong sense of ... ,Bart Weetjens, a former industrial designer, developed the idea ... land mines, after he visited minefields and saw German ...
    ... may be the disease generally identified with the third ... its tentacles everywhere. US authorities fear that an American ... flights this month to the potentially lethal disease. The ... authorities are looking for travelers who were aboard Air ...
    ... accumulating that depression is a risk factor for osteoporosis, ... Watch. A recent study found that people ages ... serotonin reuptake inhibitors (SSRIs) had double the rate of ... points to depression itself as a source of endocrine ...
    Cached Medicine News:Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 2Health News:Researchers Found Drug Effects of Deadly Prescription Well Before FDA 3Health News:Researchers Training Rats To Diagnose TB 2Health News:American Who Exposed Air Passengers to Drug Resistant TB Quarantined 2Health News:American Who Exposed Air Passengers to Drug Resistant TB Quarantined 3
    These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
    ... Anti-HTLV Mixed Titer Performance Panel consists of ... to strong positive for antibodies to HTLV ... for use by manufacturers and diagnostic laboratories ... data from all major test systems are ...
    Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
    The Repliform Tissue Regeneration Matrix is an acellular human dermal allograft that when surgically implanted is intended to function as a template, facilitating the body's fibroblasts to regenerate...
    Medicine Products: